Ferroptosis plays an essential role in chronic liver diseases, and cyclooxygenase-2 (COX-2) affects liver fibrosis through multiple mechanisms. However, research on COX-2 regulation of ferroptosis ...

With the FDA's review complete, Delcath is now cleared to initiate patient enrollment in the U.S. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC ...

GSK Plc agreed to buy an experimental medicine to treat liver diseases for as much as $2 billion as the UK drugmaker seeks to ...

The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient pool and evolving healthcare infrastructure. However, ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...